ATR Earnings Prediction
The chart below shows how ATR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ATR sees a +0.10% change in stock price 10 days leading up to the earnings, and a +3.41% change 10 days following the report. On the earnings day itself, the stock moves by -0.29%. This data can give you a slight idea of what to expect for the next quarter's release.
ATR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
848.09M
1.15%
-6.73%
Gross Margin
30.89%
4.50%
-1.03%
Operating Margin
14.56%
11.15%
-5.64%
Net Margin
11.89%
60.24%
8.19%
EPS
1.48
59.14%
0.00%
No Data Available
ATR Earnings Analysis
Aptargroup Inc Corporation (ATR.N) Earnings Conference Call
Positive
Core Sales Growth Achievement: AptarGroup, Inc. achieved core sales growth of 2% in Q4 2024, with adjusted earnings per share of $1.52, exceeding guidance due to strong operational performance and a lower effective tax rate.
Pharma Segment Performance: The pharma segment reported an 8% core sales growth for the full year, achieving an adjusted EBITDA margin of approximately 35%, driven by increased sales of higher value products and royalties.
Active Material Science Sales Growth: Active material science sales increased by 13% for the full year 2024, attributed to heightened demand for diabetes diagnostics, probiotics, and oral solid dose solutions.
Closures Segment Performance Improvement: Closures segment core sales increased by 7% year-over-year, with adjusted EBITDA margins improving by over 110 basis points for the full year, supported by a higher value mix and cost management efforts.
Shareholder Returns Increase: AptarGroup returned $183 million to shareholders in 2024 through dividends and share repurchases, marking a 20% increase from the previous year, while maintaining a strong balance sheet with a cash balance of $224 million.
Negative
Decline in Consumer Health Sales: Consumer health care core sales decreased 17%, driven by decreased demand for nasal decongestants, nasal saline room solutions, as well as cough and cold medicines due to a weaker 2023-2024 cold and flu season.
Injectables Sales Decline: Injectables core sales decreased 8% due to lower service revenue and tooling, despite a slight increase in injectable component sales.
Beauty Segment Sales Decline: Beauty segment core sales decreased 3% in the quarter, with lower tooling sales contributing about a third of the decrease, particularly in higher value prestige products.
Beauty Segment Margin Decline: The beauty segment’s adjusted EBITDA margin for the quarter was 12.4%, a 230 basis point decline, primarily due to the top-line shortfall in higher-priced prestige products.
Earnings Per Share Impact: First quarter adjusted earnings per share are expected to be negatively impacted by significant foreign currency effects and a higher effective tax rate, with an anticipated $55 headwind on EPS.
ATR FAQs
How does ATR typically perform around its earnings report dates?
Is Aptargroup Inc (ATR) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ATR Earning Call Sentiment
AptarGroup, Inc. (NYSE:ATR) Q4 2024 Earnings Call Transcript
ATR.N
-0.69%Positive
The earnings call presents mixed signals. Strong financial performance with a significant increase in adjusted EPS and growing pharma segment are positives. However, concerns about the beauty segment, unfavorable currency effects, and higher taxes pose risks. The Q&A section shows cautious optimism but lacks clarity on some financial impacts. Shareholder returns are strong, but the market may react to uncertainties in guidance and potential headwinds. Overall, the sentiment is balanced, leading to a neutral prediction for the stock price movement.
